A groundbreaking oral medication has demonstrated significant promise in extending the lives of patients with advanced pancreatic cancer, according to results from a major clinical trial involving 500 participants. The experimental drug, daraxonrasib, nearly doubled survival time compared to traditional chemotherapy treatments in patients whose metastatic cancer had stopped responding to previous therapies.
The study revealed that patients taking the daily pill survived for a median of 13.2 months, compared to 6.7 months for those receiving chemotherapy. The research findings were published in the New England Journal of Medicine and presented at the American Society for Clinical Oncology meeting in Chicago.
Daraxonrasib works by blocking a mutated protein responsible for tumor growth in more than 90 percent of pancreatic cancer cases. This protein, linked to mutations in the RAS gene family, particularly KRAS mutations, had been considered untreatable for decades due to its structure that prevented drugs from effectively binding to it. The new medication uses a novel approach, employing what researchers describe as molecular glue to bind with multiple KRAS subtypes.
Dr. Zev Wainberg from the University of California, Los Angeles, who helped lead the study, characterized the development as a very large step forward in pancreatic cancer treatment. While acknowledging that the drug does not cure the cancer, he emphasized its significance as the first medication to show substantial advantage over chemotherapy in this patient population.
Beyond survival benefits, patients taking daraxonrasib reported improved quality of life, experiencing less pain as their tumors shrank. The drug’s effects allowed patients to remain on treatment significantly longer than those receiving chemotherapy. Many participants were still using the medication when the data analysis concluded, suggesting the survival gap may continue to widen as researchers maintain their monitoring.
The most common side effects associated with the pill include potentially severe rash and mouth sores. Despite these challenges, the overall side effect profile was considered less severe than traditional chemotherapy.
Dr. Brian Wolpin of the Dana-Farber Cancer Institute, who presented the findings, suggested the drug should become a new standard of care for previously treated metastatic pancreatic cancer. Researchers are now exploring its potential use in earlier disease stages, including investigating whether tumor shrinkage might enable more patients to qualify for surgical intervention.
The Food and Drug Administration has announced plans to expedite review of daraxonrasib and has implemented an expanded access program allowing qualifying patients to receive the experimental treatment before formal approval. Revolution Medicines, the drug’s manufacturer, funded the study.
Pancreatic cancer remains one of the most lethal cancer types, primarily because detection typically occurs after the disease has spread to other organs. The American Cancer Society projects approximately 67,000 new diagnoses in the United States this year, with more than 52,000 expected deaths. The five-year overall survival rate stands at just 13 percent.
The development represents a potential turning point in pancreatic cancer treatment, with dozens of experimental drugs currently in development targeting similar pathways. Other approaches being investigated include vaccines designed to prevent recurrence after surgery by training the immune system to recognize mutated proteins.
Oncology specialists not involved in the research have expressed optimism about the findings, noting that pancreatic cancer has historically been more challenging to treat than other cancers that have benefited from various chemotherapy alternatives.
Leave a Reply